Connect Biopharma Holdings Ltd - ADR

Connect Biopharma Holdings Ltd - ADR

CNTB

Get informed when a big investor buys or sells

+ Follow
Market Cap$148.59M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Connect Biopharma Holdings Ltd - ADRConnect Biopharma Holdings Ltd - ADR-2.7--357%--
$6.50

Target Price by Analysts

167.5% upsideConnect Biopharma Holdings Target Price DetailsTarget Price
$0.68

Current Fair Value

72.2% downside

Overvalued by 72.2% based on the discounted cash flow analysis.

Share Statistics

Market cap$148.59 Million
Enterprise Value$122.18 Million
Dividend Yield$- (-)
Earnings per Share$-1
Beta-0.22
Outstanding Shares62,884,000

Return

Return on Equity-357.33%ROE
Return on Assets-220.79%
Return on Invested Capital-363.38%

Valuation & Multiples

P/E Ratio-2.68P/E Ratio
PEG-7.89PEG
Price to Sales-Price to Sales
Price to Book Ratio-Price to Book Ratio
Enterprise Value to Revenue63.9
Enterprise Value to EBIT-1.24
Enterprise Value to Net Income-2
Total Debt to Enterprise0
Debt to Equity0.02Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
August 12, 2026
EPS Estimate
$-0.31
Average shareholder expectation
Revenue Estimate
$743,308
Average shareholder expectation

Next Earnings Call

Expected Date
September 15, 2026
EPS Estimate
$-0.04
Average shareholder expectation
Revenue Estimate
$9,810
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.4041 40.41%
Total Calls196,500 8.20%
Total Puts79,400 Infinity%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %22.90% 7.69%
Total Invested$32.37M 35.57%
Investors Holding46 15.00%

ESG Score

No data

About Connect Biopharma Holdings Ltd

Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients living with chronic inflammatory diseases through the development of therapies derived from its T cell-d...